1 / 85

Outline

Vaccines and Related Biological Products Advisory Committee Meeting Clinical Review of Data Supporting the Immunogenicity, Safety and Effectiveness of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted Andrea James, M.D. FDA/CBER/OVRR/DVRPA November 14, 2012. Outline. Product Information

lenka
Télécharger la présentation

Outline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vaccines and Related Biological Products Advisory Committee MeetingClinical Review of Data Supporting the Immunogenicity, Safety and Effectiveness of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted Andrea James, M.D.FDA/CBER/OVRR/DVRPANovember 14, 2012

  2. Outline • Product Information • Q-Pan-H5N1-001 and Q-Pan-002 Immunogenicity • Arepanrix™ (Q-Pan-H1N1+AS03A) Effectiveness Study • Q-Pan-H5N1-001 and -002 Safety • Solicited reactions • Unsolicited, medically attended and serious adverse events • Additional Safety Evaluations • Adverse Events of Special Interest (AESI)/potential Immune Mediated Diseases (pIMDs) • Integrated Summaries of Safety (ISS) • Post-marketing safety of Arepanrix™ and Pandemrix™ • Post-marketing Pharmacovigilance Plan • Discussion topics for the committee

  3. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted • GSK’s candidate monovalent, pandemic influenza vaccine • Manufactured in Quebec, Canada using the licensed Flulaval™ process

  4. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted • Proper Name: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted • Trade Name: None • Naming Convention:Q(Quebec-manufactured) + Pan (pandemic vaccine) + subtype = “Q-Pan H5N1” • This discussion: Assume that the full dose of the adjuvant (AS03A) is added unless otherwise noted.

  5. Q-Pan-H5N1 • An inactivated, split virion A/H5N1 influenza virus antigen mixed with AS03 • AS03: an oil-in-water emulsion adjuvant containing: • Squalene - an unsaturated, metabolizable oil extracted from shark liver • D,L-Alpha-tocopherol (Vitamin E) • Polysorbate 80 • Thought to enhance both innate and adaptive immune responses by enhancing delivery of antigen to antigen presenting cells.

  6. Q-Pan H5N1 GSK’s Proposed Indication: • Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is a vaccine indicated for active immunization for the prevention of disease in persons 18 years of age and older at increased risk of exposure to influenza A virus H5N1 subtype contained in the vaccine.

  7. Q-Pan H5N1 • Proposed Dosage:3.75μg H5N1 HA + AS03 • Antigen dose assessed in Study D-Pan-H5N1-007 • Dresden manufactured pandemic vaccine (D-Pan) • A/Vietnam H5N1 strain • Hemagglutinin-inhibiting (HI) antibody responses were • Assessed across doses: 3.75 μg, 7.5 μg,15 μg and 30μg H5N1 HA with and without AS03A • HI antibody responses were low across all doses without AS03A adjuvant • antigen dose-dependent fashion • HI antibody responses were high independent of the antigen dose with AS03A adjuvant

  8. Q-Pan-H5N1 • Vaccine Presentation: • Separate vials of H5N1 antigen and AS03 adjuvant • Mixed 1:1 volume prior to administration. • Proposed Administration: Two 0.5 mL intramuscular injections administered 21 days apart.

  9. Studies Q-Pan-H5N1-001 and -002

  10. Study Q-Pan H5N1-001 and -002Common Trial Elements • Conducted at multiple centers in the U.S. and Canada • Randomized, controlled, single-observer-blind • Evaluated immunogenicity and safety • Vaccine/Control administered on Days 0, 21 • Q-Pan active test arms: A/Indonesia/5/2005 strain • Enrolled healthy adult males and females • Subjects with prior H5N1 vaccination excluded

  11. Study Q-Pan-H5N1-001 Design • Phase I/II • 10 U.S. and Canada sites • Adults 18-64 years old • Active control (unadjuvanted H5N1, 3.75 µg HA)

  12. Study Q-Pan-H5N1-001 Objectives • Demonstrate adjuvant activity by comparing Q-Pan H5N1 adjuvanted with AS03A(full dose)and AS03B(half dose) vs. unadjuvanted H5N1 vaccine • Demonstrate safety of Q-Pan H5N1 vs. unadjuvanted H5N1 vaccine • Demonstrate immunologic equivalence of Q-Pan H5N1 vs. D-Pan H5N1

  13. Study Q-Pan-H5N1-001Enrollment • 680 subjects enrolled 1:2:2:2:2 to: • unadjuvanted H5N1 vaccine(n=78) • Q-Pan (AS03A)(n=152) • Q-Pan (AS03B)(n=151) • D-Pan (AS03A)(n=151) • D-Pan (AS03B) (n=148)

  14. Study Q-Pan-H5N1-001 Demographics and Disposition • Mean age: 38.6 years • 54.6% of subjects were 18 – 40 years • Women: 57.8% • Caucasian: 86.8% • Disposition: • 97.8% received 2 doses of vaccine • 99% completed the study through Day 42. • 97.4% completed the study through Day 182. • No subjects withdrew due to an AE

  15. Study Q-Pan-H5N1-001 Immunogenicity Evaluations and Endpoints • Immunogenicity evaluations: Days 0, 21, 42 and 182 • Primary Endpoint • Vaccine-homologous virus antibody response in subjects receiving 2 doses of study vaccine, as demonstrated by the HI antibody titer at Day 42. • Secondary Endpoints • HI antibody response after a single dose of vaccine. • Persistence of HI antibody response 6 months post dose 1.

  16. Study Q-Pan-H5N1-001Immunogenicity Success Criteria • Demonstration of AS03 adjuvant activity • Supported if on Day 42 after two doses of study vaccine: • Lower bound of 95% CI of the difference in (Q-pan H5N1 – unadjuvanted H5N1) seroconversion rates (SCR)1 > 15% AND • Lower bound of 95% CI around the geometric mean titer (GMT) ratio (Q-Pan H5N1/unadjuvanted H5N1) > 2 • SCR = % of subjects with a pre-vaccination HI titer <10 and a post-vaccination titer ≥40 or with a pre-vaccination HI titer (Day 0) ≥10 and a fold-increase (post/pre) ≥4.

  17. Study Q-Pan-H5N1-001Immunogenicity Analysis Population • According-To-Protocol Cohort for Analysis of Immunogenicity (ATP-I) population: • Met all eligibility criteria • Complied with protocol procedures • No elimination criteria met • Provided a complete set of immunogenicity endpoint measures at Day 0 and Day 42 • Received the correct vaccine

  18. Study Q-Pan-H5N1-001Primary Immunogenicity Results: Day 42 • Activity of AS03 demonstrated • Difference in SCRs • 79.9% (95% CI = 69.4-87.3%) • Exceeded pre-specified difference of Q-Pan H5N1 (AS03A) – unadjuvanted H5N1 LBs > 15 • Adjusted GMT ratio • 43.4 (95% CI = 29.9-62.9) • Exceeded pre-specified difference of Q-Pan H5N1 (AS03A)/unadjuvanted H5N1 LB of > 2

  19. Study Q-Pan-H5N1-001Secondary HI Immunogenicity Results N = number of subjects with available data n = number of responders

  20. Q-Pan-H5N1-001 GSK’s post hoc Immunogenicity Analysis • Adjuvant effect of AS03A vs. AS03B • By age strata 18-40 yrs vs. 41-64 yrs. • AS03B performed less well in the older cohort • Lower GMTs as compared to AS03A • AS03A: 364.1 (299.2, 443.1) vs. AS03B: 209.7 (160.4, 274.2) • Results supported moving forward with AS03A in the adult population.

  21. Q-Pan-H5N1-001 Immunogenicity Conclusion • -001 Immunogenicity data supported: • Selected antigen dose: 3.75 μg • Selected adjuvant dose: AS03A • Need for two doses of vaccine to produce an adequate HI antibody response

  22. Study Q-Pan-H5N1-002 Design • Phase III • 40 U.S. and Canada sites • Adults > 18 years old • Control: saline placebo • Immunogenicity evaluations: Days 0, 21, 42 and 182

  23. Study Q-Pan-H5N1-002 Enrollment • Total N = 4,561 • Stratified by age: 18 – 64 and > 64 years • Randomization 3:1 • Q-Pan H5N1 (N = 3422) • Saline placebo (N = 1139) • Immunogenicity subset: N=2,083 • Lot consistency subset: N=1,260

  24. Study Q-Pan-H5N1-002 Objectives • Demonstrate an immune response that met CBER’s suggested immunogenicity criteria to support accelerated approval of a pandemic influenza vaccine • Demonstrate lot consistency for 3 antigen and 3 adjuvant lots* • Demonstrate the safety of Q-Pan vs. saline placebo *Lot consistency was met

  25. Study Q-Pan-H5N1-002 Demographics and Disposition • Mean age: • 39 years (18 – 64 years) • 72 years (> 64 years) • Women: 56% • Caucasian: • 86% (18-64 years) • 94% (> 64 years) • Disposition: • 97% received 2 doses of vaccine • 98% completed the study through Day 42 • 95.2% completed the study through Day 182 • 76.2% completed the study through Day 364* *Study Q-Pan-H5N1-002 was amended to add a safety evaluation on Day 364 and subjects needed to be reconsented.

  26. Q-Pan-H5N1-002Immunogenicity Endpoints • Primary endpoints (D42 - 21 days post Dose 2) • Vaccine-homologous virus HI seroconversion rates • Proportion of subjects with vaccine-homologous virus HI reciprocal titers ≥ 40 • The GMT ratio of vaccine-homologous virus reciprocal HI titers with 2-sided 95% CIs within 0.67 to 1.5 for lot consistency • Secondary endpoints included • Persistence of HI antibody response through 6 months post Dose 1

  27. Immunogenicity Success Criteria1 • These criteria and the 1:40 HI antibody titer are borrowed from seasonal influenza. • Historical data suggest that at a titer of 1:40 ~50% of subjects may be protected from illness due to seasonal influenza virus. 1Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines (2007) 2SCR = % of subjects with a pre-vaccination HI titer <10 and a post-vaccination titer ≥40 or with a pre-vaccination HI titer (Day 0) ≥10 and a fold-increase (post/pre) ≥4.

  28. Study Q-Pan-H5N1-002 Primary Immunogenicity Results N – Number of subjects with both pre- and post- vaccination results available n – number of responders

  29. Q-Pan-H5N1-002 Day 182 Immunogenicity Results N – Number of subjects with both pre- and post- vaccination results available n – number of responders number of seroconverters ** number of subjects w/ HI titer > 1:40

  30. Summary of Q-Pan-H5N1 Immunogenicity • Q-Pan H5N1 • Antigen dose sparing (3.75 μg/dose) • Two doses of vaccine are needed • Achieve an adequate HI antibody response • Exceed CBER’s suggested immunogenicity criteria.

  31. Vaccine Effectiveness

  32. ArepanrixTM (H1N1+AS03A)Effectiveness Study • “A Test-negative Case-Control Study to Evaluate the Effectiveness of GSK Biologicals’ Adjuvanted Monovalent Inactivated H1N1 Influenza Vaccine (ArepanrixTM) in Young Children (6 months to < 10 years of age)” • Sponsored by: New Brunswick Department of Health Canada • Conducted by: Dr. Van Buynder, et al

  33. Arepanrix (H1N1+AS03A)Effectiveness Study • GSK did not participate in the study conduct • CBER did not provide input into the study design • Safety data were not collected • Arepanrix evaluated at a single, 0.25 mL dose (1.9μg H1N1 HA+ AS03B)

  34. Arepanrix (1.9 H1N1+AS03B)Effectiveness Study Population • Of the ~73,000 children aged 6 months to 9 years in New Brunswick • 116 (0.16% of total population) were tested for H1N1 • Eligible for the study (n=116) • 91 children met study criteria and agreed to participate • 28 cases -- PCR confirmed H1N1+ nasal swabs • 63 controls -- PCR negative for H1N1

  35. Arepanrix (1.9 H1N1+AS03B)Effectiveness Results • When subjects were vaccinated > 14 days prior to symptom onset: • Estimated vaccine effectiveness (VE) = 100% (95% CI: 79.5,100) • When subjects were vaccinated > 10 days prior to symptom onset: • Estimated VE = 96% (95% CI: 66, 99.4)

  36. Arepanrix (1.9 μg H1N1+AS03B)Effectiveness Study • Limitations of the study • Small sample size • Large percentage of subjects excluded from the effectiveness analysis • Potential for bias e.g. selection, reporting • Retrospective study design • Conclusions: • Study suggests a single, 0.25mL dose of Arepanrix H1N1 was effective against H1N1 influenza virus in this small, study in children • Given limitations, CBER is unable to use the results of this study to confirm effectiveness of Q-Pan H5N1

  37. Safety Results of Studies Q-Pan-H5N1-001 and -002

  38. Studies Q-Pan-H5N1-001 and -002Primary Safety Population • Total Vaccinated Cohort (TVC) • Received at least 1 dose of vaccine • Any post-vaccination data • Based on treatment actually received.

  39. Studies Q-Pan-H5N1-001 and -002Safety Evaluations • Safety evaluations: • Days 0-6 diary card solicited reactogenicity events • Days 0-84 unsolicited adverse events (AEs) • Days 0 – 182 medically attended and serious AEs (-001) • Days 0 - 364 medically attended and serious AEs (-002)

  40. Studies Q-Pan-H5N1-001 and -002Solicited AE Grading • Severity grading • Mild (Grade 1) – no interference with normal activities • Moderate (Grade 2) – some interference with normal activities • Severe (Grade 3) – prevented normal activity • Redness and swelling • Grade 3 -- > 100 mm

  41. Study Q-Pan-H5N1-001: Local Reactions By Subject for Dose 1 or Dose 2 N = number of subjects with at least one documented dose n = number of subjects reporting AE at least once Any = any grade Gr 3 - Grade 3, severe

  42. Study Q-Pan-H5N1-001: Systemic Reactions By Subject for Dose 1 or Dose 2 N = number of subjects with at least one documented dose n = number of subjects reporting AE at least once Any = any grade Gr 3 - Grade 3, severe

  43. Study Q-Pan-H5N1-001: Systemic Reactions By Subject for Dose 1 or Dose 2 N = number of subjects with at least one documented dose n = number of subjects reporting AE at least once Gr 3 - Grade 3, severe

  44. Study Q-Pan-H5N1-001:Reactogenicity Event Outcomes • Antipyretics required : • 32% of Q-Pan H5N1 (AS03A) subjects vs. 21% unadjuvanted H5N1subjects • Q-Pan H5N1 (AS03A) subjects • Resolved in a median of: 3 days • No medical attention needed

  45. Study Q-Pan-H5N1-001: AEs and MAEs • Unsolicited AEs reported (by subject) • Day 42: Q-Pan H5N1 (AS03A) – 44% and unadjuvanted H5N1 -- 39% • Day 84: Q-Pan H5N1 (AS03A) – 51% and unadjuvanted H5N1 -- 45% • Events occurring exclusively in Q-Pan (AS03A) subjects (2 – 3%) • Diarrhea, anemia, lymphadenopathy, dizziness, muscle spasms and sinusitis • MAEs reported (by subject) • Day 42: Q-Pan H5N1 (AS03A) – 7% and unadjuvanted H5N1 -- 12% • Day 182: Q-Pan H5N1 (AS03A) – 19% and unadjuvanted H5N1 -- 21%

  46. Study Q-Pan-H5N1-001:SAEs • SAEs (through Day 182) • 3 SAEs in 2 Q-Pan H5N1 (AS03A)subjects • Cholelithiasis and pancreatitis(1) and Chest pain (1) • Deemed vaccine unrelated by investigators • No deaths were reported.

  47. Study Q-Pan-002: Local Reactions By Subject, Dose 1 or Dose 2 N = number of subjects with at least one documented dose n = number of subjects reporting reaction at least once Any = any grade Gr > 2 – at least moderate, Grade 2 Gr 3 - Grade 3, severe

  48. Study Q-Pan-002: Systemic Reactions By Subject, Dose 1 or Dose 2 N = number of subjects with at least one documented dose n = number of subjects reporting reaction at least once Any = any grade Gr > 2 – at least moderate, Grade 2 Gr 3 - Grade 3, severe

  49. Study Q-Pan-002 Safety: Systemic Reactions By Subject, Dose 1 or Dose 2 (cont) N = number of subjects with at least one documented dose n = number of subjects reporting reaction at least once Gr > 2 – at least moderate, Grade 2 Gr 3 - Grade 3, severe

  50. Study Q-Pan-H5N1-002: Unsolicited AEs • Day 42: Q-Pan H5N1 (38%) and saline placebo (35%) • Day 84: Q-Pan H5N1(43.4%) and saline placebo (39.6%) • Imbalances in unsolicited adverse events • Most common imbalances (by subject) occurred in the preferred terms • Injection site pruritus: Q-Pan 1.64% (n=64) vs. placebo 0.35% (n=4) • Injection site warmth: Q-Pan 1.34% (n=46) vs. placebo 0.18% (n=2) • Insomnia: Q-Pan 0.4% (n=14) vs. placebo 0.09% (n=1)

More Related